Dr. David van Duin and the Infectious Diseases Clinical Trial Team at the University of North Carolina
David van Duin, MD, PhD, FIDSA, FAST
Professor of Medicine
Director, Immunocompromised Host Infectious Diseases Program
Associate Chief, Division of Infectious Diseases
University of North Carolina
Chapel Hill, NC
1. What is your specialty and your primary area of focus?
- Infectious Diseases (ID)
- Immunocompromised host ID
2. Please tell us a bit about UNC Health.
UNC Health is a not-for-profit integrated system owned by the state of North Carolina and based in Chapel Hill. UNC Health includes 16 hospitals on 20 campuses across the state, the UNC provider network, and the clinical programs of the UNC School of Medicine.
3. Please tell us about your research team—sub- or co-investigators, key study coordinators, research nurses, and others—who play a vital role in ARLG studies.
UNC has participated in a number of ARLG studies. The team for those studies included Luther Bartelt, Heather Henderson, Natalie Mackow, Courtney Luterbach, Rima Shrestha, Trieu-Vi Khuu, Dylan Brown, Laura Ruegsegger, Ami Shiddapur, and Ashley Boshe.
4. Which ARLG projects have you participated in as a clinical trial site?
| Study Name | Full Title |
| CRACKLE | Consortium on Resistance against Carbapenems in Klebsiella pneumoniae |
| CRACKLE II | Consortium on Resistance against Carbapenems in Klebsiella pneumoniae and other Enterobacteriaceae |
| EVADE | Effort to Prevent Nosocomial Pneumonia caused by Pseudomonas aeruginosa in Mechanically Ventilated Subjects |
| GENO-STELLAR | GENOmics, Sequencing-based Typing, EpidemioLogy, Linkage, and Antimicrobial Resistance Tool |
| POP-MDRO | Prospective Observational Pseudomonas study - Multi-Drug Resistant Organism Network |
| RADICAL II | Rapid Diagnostic in Categorizing Acute Lung Infections |
| SAATELITTE | Staphylococcus aureus Alpha Toxin in Mechanically Ventilated Adult Subjects |
| SCENE | Screening for Colonization with Resistant Enterobacterales in Neutropenic Patients with Hematologic Malignancies |
| SHREC-MDRO | Multi-Drug Resistant Organism (MDRO): Study of Highly Resistant Escherichia coli |
| SNAP-MDRO | Study Network of Acinetobacter baumannii as Carbapenem-Resistant Pathogen as part of the Multi-Drug Resistant Organism Network |
Learn more on the ARLG Studies page and on the Summary of Results page.
5. Have you been involved with the ARLG in another capacity?
Within the ARLG, I serve on the Executive, Steering, and Publication Committees. I have also served in several other roles including Associate Director of the Clinical Operations Center, Principal Investigator for the MDRO Network and the CRACKLE and SHREC studies, and member of the Gram-Negative Sub-Committee, Phage Task Force, Immunocompromised Host Working Group, and the Clinical Indications Phage Subgroup.
6. Why is the mission of ARLG important to you?
Antimicrobial resistance is a global threat to health. ARLG facilitates multi-center collaborations that provide a positive impact by improving the prevention, diagnosis, treatment, and outcomes of infections caused by resistant bacteria.
7. Is there anything else you’d like to share about your work with the ARLG?
Working within such a large group of dedicated leaders in the field of antimicrobial resistance is truly inspiring, and I am most grateful for the support I have received over the years from ARLG and the NIH.